When should Donepezil hydrochloride 23 mg oral tablet be discontinued in a patient with dementia?

When to Discontinue Donepezil 23 mg in Dementia Patients

Discontinue donepezil 23 mg when adverse effects are intolerable (particularly gastrointestinal symptoms in the first month), when the patient progresses to very severe dementia where slowing decline is no longer a meaningful goal, or when there is clear evidence of treatment failure after 3 months of therapy.

Decision Framework for Discontinuation

1. Adverse Event-Related Discontinuation

The 23 mg dose has a significantly higher discontinuation rate (19%) compared to 10 mg (8%) 1. Most discontinuations occur within the first month of treatment 1.

Discontinue immediately if:

• Vomiting (3% discontinuation rate at 23 mg vs 0% at 10 mg)
• Severe diarrhea (2% vs 0%)
• Intractable nausea (2% vs 0%)
• Dizziness causing functional impairment (1% vs 0%)
• Serious adverse events including cardiac conduction abnormalities, severe bradycardia, or extrapyramidal symptoms 1, 2

Common pitfall: The FDA label clearly shows that gastrointestinal adverse events (nausea 12%, vomiting 9%, diarrhea 8%) are dose-dependent and occur at 3-4 times the rate of the 10 mg dose 1. Don't persist through severe symptoms—consider dose reduction to 10 mg rather than complete discontinuation if cognitive benefits were evident.

2. Treatment Ineffectiveness

Assess response at 3 months 3. The guideline states that "a beneficial effect, if any, would generally be observed within 3 months" 3.

Discontinue if:

• Progressive cognitive decline despite treatment (no stabilization or improvement)
• No functional benefit observed by caregivers
• Patient has advanced to very severe dementia (CDR = 3), where ineffectiveness becomes the primary reason for discontinuation 4

Critical evidence: In patients with moderate to severe AD, continuing donepezil showed cognitive benefits exceeding the minimum clinically important difference (1.9 points on SMMSE) and functional benefits (3.0 points on BADLS) over 12 months 5. This high-quality 2012 RCT demonstrates that discontinuation in moderate-severe disease leads to measurable decline, so don't stop prematurely if the patient is tolerating the medication.

3. Disease Severity Considerations

Consider discontinuation when:

• Patient reaches very severe dementia where "slowing decline is no longer a goal" and quality of life is judged to be poor 3
• Family/caregivers no longer view stabilization as desirable given poor quality of life 3
• Patient develops severe dysphagia requiring alternative routes (though transdermal patches are available) 6

Evidence shows: Patients with CDR = 3 (severe dementia) discontinue earlier and more frequently, with ineffectiveness being the major reason 4. However, the 2012 DOMINO trial 5 demonstrated continued benefit even in moderate-severe disease, so base this decision on individual functional status rather than severity scores alone.

4. Behavioral and Psychological Symptoms

Paradoxically, consider discontinuation if:

• Development of severe behavioral and psychological symptoms of dementia (BPSD) during donepezil therapy
• Agitation and irritability worsen on treatment

One study showed that discontinuing donepezil in severe AD patients with BPSD led to significant decreases in agitation and irritability without requiring increased doses of other psychotropic medications 7. This represents a specific scenario where discontinuation may improve quality of life.

5. Contraindications and Drug Interactions

Discontinue if patient develops:

• Uncontrolled asthma
• Angle-closure glaucoma
• Sick sinus syndrome or left bundle-branch block 3
• Need for anticholinergic medications that would antagonize donepezil's effects 1

Practical Monitoring Algorithm

First Month (highest risk period):

• Weekly assessment for GI symptoms, dizziness, weight loss
• Monitor for discontinuation-worthy adverse events (see above)

At 3 Months:

• Formal cognitive assessment (MMSE or equivalent)
• Functional assessment (ADLs)
• If no benefit or continued decline: discontinue or reduce dose

Ongoing:

• Reassess treatment goals as disease progresses
• When patient reaches very severe dementia, have explicit discussion with family about whether slowing decline remains a meaningful goal

Key Caveats

• Don't discontinue due to administrative reasons (change of doctors was the most common reason for discontinuation in one study 4, but this is inappropriate)
• The 23 mg dose is specifically for moderate to severe AD—it's not appropriate for mild disease 1
• Evidence for optimal duration is insufficient 3, but the 2012 RCT showed benefits continuing through 12 months 5
• Consider dose reduction to 10 mg before complete discontinuation if adverse effects are the only concern but some benefit was observed

The guideline emphasizes that treatment decisions should balance "harms against modest or even no benefit" 3, but the most recent high-quality evidence 5 demonstrates clinically meaningful benefits in moderate-severe disease, supporting continuation unless specific discontinuation criteria are met.